880160-69-0

Usage

Uses

Used in Pharmaceutical Industry:
[4-(8-fluoro-6-oxo-3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indol-2-yl)-benzyl]-methyl-carbamic acid methyl ester is used as a potential drug development candidate for its possible impact on various biological processes. [4-(8-fluoro-6-oxo-3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indol-2-yl)-benzyl]-methyl-carbamic acid methyl ester's unique structure, including the azepinoindole core, may offer novel therapeutic opportunities once its properties and applications are fully understood.
Used in Research and Development:
In the field of scientific research, [4-(8-fluoro-6-oxo-3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indol-2-yl)-benzyl]-methyl-carbamic acid methyl ester serves as a tool compound. Its complex structure and potential to interact with biological systems make it valuable for exploring new avenues in drug discovery and understanding the underlying mechanisms of various diseases.

Upstream product

• 283173-80-8 2-bromo-8-fluoro-1,3,4,5-tetrahydro-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one 
• 68162-47-0 4-bromomethylphenylboronic acid 
• 128399-19-9 4-formylphenyl boronic acid diethanolamine ester 
• 1122-91-4 4-bromo-benzaldehyde 
• 699-03-6 N-methyl-4-bromobenzylamine 
• 87199-17-5 4-formylphenylboronic acid, 
• 880160-68-9 6-fluoro-2-{4-[(methoxycarbonyl-methyl-amino)-methyl]-phenyl}-3-(2-nitro-ethyl)-1H-indole-4-carboxylic acid methyl ester 

Downstream Products

• 283173-50-2 Rucaparib 

Relevant academic research and scientific papers

Preparation method ofdrug Rucaparib for treating ovarian cancer

The invention discloses a preparation method of drug Rucaparib for treating an ovarian cancer. The method comprises the following steps that step 1, a compound A and a compound B with a PG protectinggroup are acylated in an organic solvent a under the action of an acid binding agent, and a compound of a formula I is prepared; step 2, an enamine bond of the compound of the formula I is hydrolyzedin an aqueous organic solvent b under the action of acid c to obtain a compound of a formula II; step 3, after the reduction of a nitro group to an amino group of the compound of formula II under theaction of a reducing agent, cyclodehydration is conducted to obtain a compound of a formula III; step 4, the compound of the formula III and N-(2-acetaldehyde) phthalimide are condensed under the action of acid d to obtain a compound of a formula IV; step 5, the compound of the formula IV is cyclized to obtain a compound of a formula V while removing the phthaloyl protecting group; step 6, the PGprotecting group of the compound of the formula V is removed to obtain the Rucaparib. The method reduces the cost of producing the drug Rucaparib for treating the ovarian cancer.

METHODS AND INTERMEDIATES FOR PREPARING RUCAPARIB

The present invention relates to a process for preparing rucaparib or pharmaceutically acceptable salts thereof. It also provides novel intermediates that may be converted into rucaparib or pharmaceutically acceptable salts thereof.

Method of preparing poly(ADP-ribose) polymerases inhibitors

This invention relates to a new and convergent route to small molecule inhibitors of poly(ADP-ribose) polymerase, such as 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, via a key Sonogashira coupling reaction and a CuI-promoted indole formation.